Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HIVIS DNA HIV-1 vaccine
- Development stage
- Unknown
- Lead developer
- Karolinska Institutet
- Modality
- DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intradermal, Intramuscular
01
Overview
The HIVIS DNA HIV-1 vaccine is a multigene, multiclade plasmid DNA-based vaccine developed by the Swedish Institute for Infectious Disease Control (SMI) in collaboration with Karolinska Institutet and Karolinska University Hospital. It consists of seven plasmids encoding multiple HIV-1 antigens, including envelope gp160 of subtypes A, B, and C; Rev B; Gag A and B; and a mutated reverse transcriptase (RTmut) B. The vaccine is designed to stimulate endogenous production of these HIV-1 proteins to elicit broad cellular and humoral immune responses. In clinical trials, such as the HIVIS 01/02 Phase I study, the vaccine was evaluated as a prime in a DNA-prime/MVA-boost strategy, often incorporating recombinant GM-CSF as an adjuvant to enhance immunogenicity. It is intended for prophylactic use against HIV-1 infection and AIDS.
- Other names
- HIVIS DNA vaccineHIVIS 01/02 DNA vaccine
02
Targets
CSF2R (Granulocyte-macrophage colony-stimulating factor receptor)
Beyond the preview
Go deeper on HIVIS DNA HIV-1 vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HIVIS DNA HIV-1 vaccine.